Liquidia Corp
corporate_fare Company Profile
Liquidia Corp (NASDAQ:LQDA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 35 items for LQDA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for LQDA spans 8-K, 10-Q, 4, 144.
Recent high-impact activity:
- Liquidia Q3: YUTREPIA Sales $222.7M, Adjusted EBITDA $140.5M, October Shipments at Record
- Liquidia Q3: YUTREPIA Sales Hit $222.7M, $389.7M UTC Settlement Charge Drives $236.3M Net Loss
- Liquidia Posts $2.64 Loss Per Share for Third Quarter
- Liquidia Settles All UTC Litigation for $380.7M, Preserves YUTREPIA PAH Franchise
- Liquidia Settles All Litigation With United Therapeutics for $380.7M, Securing YUTREPIA's Future
Financial Snapshot
Short Interest & Short Volume
5.29 days to coverFINRA reported short interest of 17,511,349 shares in LQDA as of the October 30, 2026 settlement, a 1.2% increase from the prior period — about 5.3 days to cover at its recent average daily volume. On November 20, 2026, 43.6% of LQDA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.